This Week in HIV Research: Prevention and Treatment in the Real World

This Week in HIV Research: Prevention and Treatment in the Real World

1 of 5
Next >

Trying to gauge real-world relevance is one of the many challenging aspects of determining the value of published research, particularly when it comes to randomized drug trials. How much of a drug's efficacy rate in these trials is real, and how much is idealized? We poke at this question with some of the new research we've chosen to highlight this week, which includes:

  • Insight into the heavy impact of intimate partner violence (IPV) on a woman's desire to take pre-exposure prophylaxis (PrEP).
  • An updated look at HIV treatment failure rates among participants in prospective first-line therapy trials during this decade.
  • An exploration of the role that low-level viremia may play over time in a person's cumulative risk of virologic failure.
  • Additional nuance into our understanding of HIV drug levels in a mother's plasma relative to breast milk.

Of course, when you're done here, be sure to hop over to our ever-expanding coverage of last week's Conference on Retroviruses and Opportunistic Infections, a.k.a. CROI 2019; news of a potential second person cured of HIV may have grabbed headlines, but there was also plenty of research presented at the meeting with much more immediate clinical relevance. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Credit: Hilch for iStock via Thinkstock

Trying to gauge real-world relevance is one of the many challenging aspects of determining the value of published research, particularly when it comes to randomized drug trials. How much of a drug's efficacy rate in these trials is real, and how much is idealized? We poke at this question with some of the new research we've chosen to highlight this week, which includes:

  • Insight into the heavy impact of intimate partner violence (IPV) on a woman's desire to take pre-exposure prophylaxis (PrEP).
  • An updated look at HIV treatment failure rates among participants in prospective first-line therapy trials during this decade.
  • An exploration of the role that low-level viremia may play over time in a person's cumulative risk of virologic failure.
  • Additional nuance into our understanding of HIV drug levels in a mother's plasma relative to breast milk.

Of course, when you're done here, be sure to hop over to our ever-expanding coverage of last week's Conference on Retroviruses and Opportunistic Infections, a.k.a. CROI 2019; news of a potential second person cured of HIV may have grabbed headlines, but there was also plenty of research presented at the meeting with much more immediate clinical relevance. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Credit: Hilch for iStock via Thinkstock